Evidence map›Paper›PMID 36373218›Full record

ArticleAdvanced healthcare materials2023

Hydrogel Microtumor Arrays to Evaluate Nanotherapeutics.

Yiling Liu, Stephanie Nemec, Chantal Kopecky, Martina H Stenzel, Kristopher A Kilian

Open access · hybridAbstract read
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yiling LiuSchool of Chemistry, The University of New South Wales, Sydney, NSW, 2052, Australia.ORCID 0000-0002-9789-1385
Stephanie NemecAustralian Centre for NanoMedicine, Sydney, NSW, 2052, Australia.ORCID 0000-0003-4610-924X
Chantal KopeckySchool of Chemistry, The University of New South Wales, Sydney, NSW, 2052, Australia.ORCID 0000-0003-2289-4837
Martina H StenzelSchool of Chemistry, The University of New South Wales, Sydney, NSW, 2052, Australia.ORCID 0000-0002-6433-4419
Kristopher A KilianSchool of Chemistry, The University of New South Wales, Sydney, NSW, 2052, Australia.ORCID 0000-0002-8963-9796
UNSW Sydney · AUCancer Institute of New South Wales · AU

Funding

Engineered microtumor arrays for development of combination therapiesR01CA251443 · NCI · UNIVERSITY OF NEW SOUTH WALES · PI COPLAND, JOHN A., KILIAN, KRISTOPHER ALAN · 2020 to 2024
$998k
NCI NIH HHS R01 CA251443NIH HHS R01CA251443
6 · The paper itself

Abstract

Nanoparticle drug formulations have many advantages for cancer therapy due to benefits in targeting selectivity, lack of systemic toxicity, and increased drug concentration in the tumor microenvironment after delivery. However, the promise of nanomedicine is limited by preclinical models that fail to accurately assess new drugs before entering human trials. In this work a new approach to testing nanomedicine using a microtumor array formed through hydrogel micropatterning is demonstrated. This technique allows partitioning of heterogeneous cell states within a geometric pattern-where boundary regions of curvature prime the stem cell-like fraction-allowing to simultaneously probe drug uptake and efficacy in different cancer cell fractions with high reproducibility. Using melanoma cells of different metastatic potential, a relationship between stem fraction and nanoparticle uptake is discovered. Deformation cytometry reveals that the stem cell-like population exhibits a more mechanically deformable cell membrane. Since the stem fraction in a tumor is implicated in drug resistance, recurrence, and metastasis, the findings suggest that nanoparticle drug formulations are well suited for targeting this dangerous cell population in cancer therapy.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsDrug Delivery SystemsHumansHydrogelsNanomedicineReproducibility of ResultsTumor MicroenvironmentAntineoplastic AgentsHydrogelsbiomaterialscancer stem cellsdrug developmentnanoparticlestumor microenvironment

Identifiers

PMID36373218
PMCPMC11323127
OpenAlexW4308955543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.